Abstract |
Blinatumomab, a bispecific antibody construct targeting CD19, is the most advanced member of bispecific T-cell engager ( BiTE(®)) molecules. The clinical development program includes B-precursor acute lymphoblastic leukemia (ALL) and B-cell non-Hodgkin lymphoma (NHL). Minimal residual disease (MRD) response in patients with MRD-positive B-precursor ALL has translated into long-term clinical benefits as demonstrated by an estimated relapse-free survival (RFS) of 60% with sustained MRD negativity at a follow-up of 31 months. Remissions induced in pediatric and adult patients with relapsed/refractory B-precursor ALL have allowed for successful allogeneic hematopoietic stem cell transplantation (HSCT) in this setting. Blinatumomab has also induced durable responses in low-grade B-cell NHL. Blinatumomab recently gained approval in the United States by the U.S. Food and Drug Administration for treatment of Philadelphia chromosome-negative B-precursor relapsed/refractory acute lymphoblastic leukemia. AMG 330 is an investigational anti-CD33 BiTE(®) antibody construct. Targeting CD33 ex vivo in primary samples from patients with acute myeloid leukemia (AML) has shown AMG 330-mediated T-cell expansion and T-cell cytotoxicity against AML cells.
|
Authors | Gerhard Zugmaier, Matthias Klinger, Margit Schmidt, Marion Subklewe |
Journal | Molecular immunology
(Mol Immunol)
Vol. 67
Issue 2 Pt A
Pg. 58-66
(Oct 2015)
ISSN: 1872-9142 [Electronic] England |
PMID | 25883042
(Publication Type: Journal Article, Review)
|
Copyright | Copyright © 2015 Elsevier Ltd. All rights reserved. |
Chemical References |
- Antibodies, Bispecific
- Antigens, CD19
- Antineoplastic Agents
- Sialic Acid Binding Ig-like Lectin 3
- blinatumomab
- AMG 330
|
Topics |
- Antibodies, Bispecific
(immunology, therapeutic use)
- Antigens, CD19
(immunology, metabolism)
- Antineoplastic Agents
(immunology, therapeutic use)
- Disease-Free Survival
- Hematologic Neoplasms
(immunology, metabolism, therapy)
- Humans
- Sialic Acid Binding Ig-like Lectin 3
(immunology, metabolism)
- T-Lymphocytes
(drug effects, immunology, metabolism)
- Treatment Outcome
|